title: [Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study].
abstract: OBJECTIVE
  To investigate the toxicity and safety of FOLFOX regimen concurrent with radiotherapy in neoadjuvant setting in patients with low rectal cancer.
  
  
  METHODS
  Fifty-six patients with stage T(3-4)N(0)M(0) and T(1-4)N(1-2)M(0) were eligible from Aug. 2004 to Jul. 2007. Upon entry the study, they received 4 cycles of chemotherapy with FOLFOX regimen. Radiotherapy was added from the second cycle of chemotherapy (CT). The total dose of radiotherapy (RT) was 46 Gy (2 Gy x 23). Total mesorectal excision (TME) was performed 4-8 weeks after RT.
  
  
  RESULTS
  Among them, 54 cases received 4 cycles of CT, 1 patient stopped CT after the second cycle of CT because of unrecovery from neutropenia. One patient stopped chemoradiotherapy(CRT) because of complicating with active pulmonary tuberculosis after 2 cycles of CT and 10 times of RT. Two occurred liver, lung and bone metastases after CT. Totally 220 cycles of CT were administrated. Fifty-two patients received operation after CRT, 50 with anal interior sphincter reservation, 19 with prophylactic ileac stoma. Anastomotic leakage occurred in 2 patients after operation, and rectal vaginal fistula in 2 patients 1 month after operation. According to the pathologic results, 7 patients achieved complete response, 41 partial response, 4 stable disease, and the objective response rate was 85.7%.
  
  
  CONCLUSIONS
  Concomitant treatment of FOLFOX regimen and RT in neoadjuvant setting of rectal cancer was safe and tolerable, and it suggests that protective ileostomy for anastomotic leakage following anus-preserving operation should be performed.
authors.affiliation: Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China. wangjianp@mail.sysu.edu.cn
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Wang
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Ding
authors.forename: Yan-Hong
authors.initials: YH
authors.lastname: Deng
authors.forename: Ping
authors.initials: P
authors.lastname: Lan
authors.forename: Kai
authors.initials: K
authors.lastname: Pan
authors.forename: Gong-Hang
authors.initials: GH
authors.lastname: Dong
authors.forename: Jian-Zhong
authors.initials: JZ
authors.lastname: Deng
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Xiao-Jian
authors.initials: XJ
authors.lastname: Wu
authors.forename: Xue-Feng
authors.initials: XF
authors.lastname: Guo
authors.forename: Jie
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005575:Formyltetrahydrofolates / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*; D012007:Rectum / Q000473:pathology; D055815:Young Adult
chemical_list: D005575:Formyltetrahydrofolates; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil